New combo therapy aims to halt spread of prostate cancer
NCT ID NCT04748042
First seen Mar 10, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study tests a treatment plan for men with prostate cancer that has spread to a few other parts of the body (oligometastatic). The treatment combines focused radiation with a hormone therapy (ADT), a drug called abiraterone, and a targeted drug called Lynparza (olaparib). The goal is to see if this combination can stop the cancer from growing for at least 24 months. About 21 men will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.